Antibody against complement protein C5 and application thereof
By developing high-affinity antibodies against complement protein C5 and combining enzyme-linked immunoassay kit technology, the problem of difficult detection of soluble membrane attack complex SC5b-9 in the prior art is solved, and effective evaluation of complement system activation is achieved and Clinical application.
Patent Information
- Application Number
- CN202411298825.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-18
AI Technical Summary
Existing technologies are difficult to effectively detect and quantitatively analyze the soluble membrane attack complex SC5b-9, affecting the evaluation of complement system activation and diagnosis of related diseases.
An antibody against complement protein C5 has been developed, with high affinity and high specificity, and can be used to quantitatively detect soluble membrane attack complex SC5b-9, and can be used to achieve detection in combination with enzyme-linked immunoassay kit technology.
It realizes efficient quantitative detection of SC5b-9, can predict the activation of the complement system in the sample, has clinical application prospects, and is suitable for the detection of plasma and other tissue samples.
Smart Images

Figure CN119019553A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field related to the detection of complement protein C5 and soluble membrane attack complex SC5b-9, and specifically to an antibody against complement protein C5 and its use. Background Art
[0002] The complement system is an important component of the body's innate immunity. It is composed of more than 50 soluble proteins and membrane-bound proteins. It plays an important role in the body's life activities such as defense against foreign substances, cell lysis, inflammatory response, dissolution of immune complexes, removal of apoptotic cells, and enhancement of humoral immune response. Complement activation occurs through three main pathways: the classical pathway, the alternative pathway, and the mannose-binding lectin (MBL) pathway.
[0003] Among them, complement protein C5 is the main component of the complement system and a key part of the innate immune system. Complement protein C5 is a 190kDa glycoprotein, containing two polypeptide chains α and β connected by disulfide bonds, with molecular masses of 115kDa and 75kDa. The arginine residue of the 74th amino acid downstream of the N-terminus of the α-chain of complement protein C5 is cleaved by C5 convertase, which cleaves C5 to produce C5a and C5b. Among them, C5a is an anaphylatoxin that can stimulate vasodilation through histamine released by basophils and giant cells; C5b binds to the cell surface and then forms a terminal complement complex (TCC) with complement proteins C6, C7, C8, and C9. TCC has two forms: (1) It exists in plasma and binds to S protein to form a soluble membrane attack complex SC5b-9; (2) It binds to the cell membrane and is composed of multiple C9 (C9n) and C5b-8 to form C5678(9)n, called membrane attack complex (MAC), which causes irreversible damage to the cell membrane and leads to cell lysis and destruction.
[0004] It can be seen from this that SC5b-9 is a hydrophilic, non-cytolytic macromolecular fragment formed by the common end product C5b-9 and S protein produced after activation of the complement system.
[0005] Among them, in terms of the way C5b-9 acts on target cells, there are full lytic and sub-lytic types. Different target cells have different results of C5b-9. When C5b-9 is assembled on the surface of anucleated cells (such as red blood cells), it can form a transmembrane channel on the cell membrane, causing the cell to lyse. When complement restriction factors (such as CD59, etc.) are present on the surface of nucleated cells, these complement regulatory proteins can prevent the polymerization of C9 molecules on the cell membrane, interfere with the formation of C5b-9, and prevent C5b-9 from inserting into the phospholipid bilayer of the target cell, causing C5b-9 to insert shallowly into the membrane and unable to cause cell perforation and rupture. This type of C5b-9 is called a sub-lytic C5b-9 complex. C5b-9 can stimulate a variety of biological activity changes in a variety of cells, including the production of inflammatory mediators, cytokines, and induction of membrane protein expression. This cell-stimulating effect of C5b-9 plays a role in the pathogenesis and progression of a variety of diseases, especially sublytic C5b-9, which has multiple pathogenic effects in diseases such as inflammation, nervous system diseases, kidney disease, and atherosclerosis.
[0006] Therefore, by detecting the content of SC5b-9 molecules in the sample, the activation of the complement system can be reflected. Summary of the invention
[0007] In view of this, the present application provides an antibody against complement protein C5 and its use. The antibody against complement protein C5 based on the present application shows high affinity and high specificity to soluble membrane attack complex SC5b-9, and can achieve quantitative detection of soluble membrane attack complex SC5b-9.
[0008] In the first aspect of the present application, the present application provides an anti-complement protein C5 antibody or an antigen-binding fragment thereof, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 in the light chain variable region of the antibody or its antigen-binding fragment are shown as SEQ ID NOs. 3, 4, and 5, respectively; the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 in the heavy chain variable region of the antibody or its antigen-binding fragment are shown as SEQ ID NOs. 9, 10, and 11, respectively.
[0009] In some specific embodiments of the present application, the amino acid sequence of the light chain variable region of the antibody or its antigen-binding fragment is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region of the antibody or its antigen-binding fragment is shown as SEQ ID NO.8.
[0010] In some specific embodiments of the present application, the amino acid sequence of the light chain constant region of the antibody is shown as SEQ ID NO. 6. In some specific embodiments of the present application, the amino acid sequence of the light chain of the antibody is shown as SEQ ID NO. 1.
[0011] In some specific embodiments of the present application, the amino acid sequence of the heavy chain constant region of the antibody is shown as SEQ ID NO. 12. In some specific embodiments of the present application, the amino acid sequence of the heavy chain of the antibody is shown as SEQ ID NO. 7.
[0012] In some specific embodiments of the present application, the antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, a monoclonal antibody, an animal-derived antibody or a humanized antibody.
[0013] In some specific embodiments of the present application, the antibody is selected from a monoclonal antibody.
[0014] In some specific embodiments of the present application, the antibody is selected from IgG antibodies.
[0015] In the second aspect of the present application, the present application provides a polynucleotide encoding the antibody or antigen-binding fragment thereof described in the first aspect of the present application.
[0016] According to the amino acid sequence of the antibody described in the first aspect of the present application, a person skilled in the art can obtain the nucleotide sequence of the polynucleotide encoding the antibody described in the first aspect of the present application. Due to the degeneracy of codons, the nucleotide sequence of the polynucleotide is not unique, and all polynucleotides capable of encoding the antibody described in the first aspect of the present application are within the scope of protection of the present application.
[0017] In the third aspect of the present application, the present application provides a biological material containing the polynucleic acid described in the second aspect of the present application.
[0018] Wherein, the biological material includes but is not limited to expression cassette, vector or host cell. The expression cassette can be obtained by connecting transcription or translation regulatory elements such as promoters upstream of the polynucleic acid and / or connecting transcription or translation regulatory elements such as terminators downstream thereof. The vector includes but is not limited to plasmid vectors, phage vectors, virus vectors, artificial chromosome vectors, etc. The host cell includes microbial cells, insect cells or other animal cells.
[0019] In the fourth aspect of the present application, the present application provides an antibody conjugate, wherein the antibody conjugate is obtained by conjugating the antibody or antigen-binding fragment thereof described in the first aspect of the present application with a marker.
[0020] In some optional embodiments of the present application, the label is selected from at least one of enzyme labeling, biotin labeling, fluorescent dye labeling, chemiluminescent dye labeling, and radioactive labeling.
[0021] In the fifth aspect of the present application, the present application provides the use of any of the following items in the preparation of a product for detecting complement protein C5 or soluble membrane attack complex SC5b-9: (I) the antibody or antigen-binding fragment thereof described in the first aspect of the present application; and / or (II), the polynucleotide described in the second aspect of the present application; and / or (III) the biological material described in the third aspect of the present application; and / or (IV) The antibody conjugate described in the fourth aspect of the present application.
[0022] In the sixth aspect of the present application, the present application provides a detection reagent for detecting complement protein C5 or soluble membrane attack complex SC5b-9, wherein the detection reagent comprises the antibody or its antigen-binding fragment described in the first aspect of the present application, and / or the antibody conjugate described in the fourth aspect of the present application.
[0023] In the seventh aspect of the present application, the present application provides a detection kit for detecting complement protein C5 or soluble membrane attack complex SC5b-9, characterized in that the kit comprises the antibody or its antigen-binding fragment described in the first aspect of the present application, and / or the antibody conjugate described in the fourth aspect of the present application.
[0024] In some optional embodiments of the present application, the detection kit is selected from an enzyme-linked immunosorbent assay kit, a fluorescent immunoassay kit or a chemiluminescent immunoassay kit.
[0025] In some optional embodiments of the present application, the detection kit is selected from an enzyme-linked immunosorbent assay kit.
[0026] This application has the following beneficial effects: First, the monoclonal antibody (anti-complement protein C5 antibody) produced by the present application with complement protein C5 as the target shows high affinity and high specificity for the soluble membrane attack complex SCb59, and the anti-complement protein C5 antibody of the present application combined with the anti-complement protein C9 antibody can achieve quantitative detection of the soluble membrane attack complex SC5b-9 to predict the activation of the complement system in the sample.
[0027] Second, the anti-complement protein C5 antibody of the present application is also specific for binding to complement protein C5, and is suitable for plasma sample detection or sample detection from other tissue sources, and has a promising clinical application prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is the standard curve for detecting soluble membrane attack complex SC5b-9 based on the double antibody sandwich method in Example 2 of the present application.
[0029] Figure 2 This is the binding activity curve of anti-complement protein C5 antibody and complement protein C5 detected based on the direct ELISA method in Example 3 of the present application. DETAILED DESCRIPTION
[0030] The present application discloses an antibody against complement protein C5 and its use. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in this application. The methods and applications of this application have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of this application to implement and apply the technology of this application.
[0031] Terminology explanation: The "antibody (Antibody, Ab)" used in this application is an immunoglobulin with immune function (i.e., it can specifically bind to the antigen) secreted by B lymphocytes after antigen stimulation. The antibody has a tetrameric structure, and the antibody contains two identical heavy chains (heavy chain, H chain) and two identical light chains (light chain, L chain). Among them, the region where the amino acid sequence of the heavy chain and light chain near the N-terminus varies greatly is called the variable region (variable region, V region), among which the amino acid sequence of the heavy chain and light chain variable region mainly has great variability in three regions, which are called hypervariable regions (hypervariable region, HVR). Since this region is the site where Ig and antigen epitopes are complementary, it is called the complementarity determining region (complementarity determing region, CDR), which is represented by HVR1 (CDR1), HVR2 (CDR2), and HVR3 (CDR3), respectively, among which CDR3 has the largest change; the region where the amino acid sequence of the heavy chain and light chain near the C-terminus is relatively constant is called the constant region (constant region, C region).
[0032] The "monoclonal antibody" used in this application is a specific antibody with a completely identical chemical structure and complementary to the antigenic determinant cluster, which is produced by B lymphocytes under the stimulation of specific antigens.
[0033] As used herein, "amino acid difference" refers to amino acid modification (such as amino acid methylation modification, etc.) or amino acid replacement.
[0034] In order to make the purpose, technical solutions and advantages of the present application clearer, the implementation scheme of the present application will be further described in detail below in conjunction with examples.
[0035] Unless otherwise specified, the recombinant human complement protein C5 used in this application was purchased from Sanyou Biopharmaceuticals (Shanghai) Co., Ltd., catalog number #P217782.
[0036] Unless otherwise specified, the horseradish peroxidase (HRP)-labeled mouse anti-goat IgG antibody used in this application was purchased from Jackson Immunoresearch Inc., catalog number #205-035-108.
[0037] Unless otherwise specified, the recombinant human complement protein C5 used in this application was purchased from Sanyou Biopharmaceuticals (Shanghai) Co., Ltd., catalog number #P217782.
[0038] Example 1 Antibody against complement protein C5: In this embodiment, the antibody against complement protein C5 is a monoclonal antibody, which is obtained by conventional mouse immunization and phage screening methods.
[0039] The method for preparing an antibody against complement protein C5 specifically comprises the following steps: S101. Female Balb / c mice aged 6 to 8 weeks were selected and recombinant human complement protein C5 was mixed with an equal volume of Freund's adjuvant and emulsified for immunization. The immunization cycle was two weeks. After three immunizations, blood was collected from the submandibular vein of the mice, and the antibody titer of the mice's immune response to recombinant human complement protein C5 was detected by the ELISA method.
[0040] S102. After five immunizations, the mice were killed by cervical dislocation, and the spleen was removed aseptically. After squeezing and grinding in a plate, Trlzol reagent was added to extract the total RNA of the mouse spleen tissue, which was reverse transcribed into cDNA to obtain the gene sequence encoding the antibody after mouse immunization.
[0041] S103. The gene sequence encoding the antibody is constructed into a phage display vector using molecular cloning technology. The constructed phage display vector is then electroporated into Escherichia coli to obtain a phage display library of mouse immune antibodies (anti-recombinant human complement protein C5).
[0042] S104. The phage library sequence is displayed on the phage surface by phage display technology. After that, the antibodies binding to the antigen are continuously enriched through multiple rounds of liquid / solid phase screening using biotinylated and non-biotinylated recombinant human complement protein C5, and the screening collection is tested by ELISA. The positive clones that specifically bind to the recombinant human complement protein C5 antigen are further screened by ELISA, and 34 positive clone antibodies are obtained by sequencing.
[0043] S105, using 34 positive cloned antibodies as templates, the antigen binding fragment (fragment of antigen binding, Fab) of the antibody molecule was obtained by PCR technology, and the heavy chain Fab fragment was connected to pcDNA3.4-HC (goat-IgG), and the light chain Fab fragment was connected to pcDNA3.4-LC (goat-Kappa), and the connected fragments were transferred to Escherichia coli culture to obtain monoclonal colonies, and single colonies were selected for sequencing and identification. Single colonies with correct sequences were used for plasmid extraction to obtain heavy chain plasmids and light chain plasmids, respectively. The heavy chain plasmid and the light chain plasmid were co-transfected into 6×10 6 The transfected cells were cultured at 37°C and 7% CO2 for 7 days, centrifuged at 15,000 g, and the cell expression supernatant was collected. The supernatant was purified with MabSelect SuRe LX (Cytiva) resin to obtain the anti-complement protein C5 antibody.
[0044] The anti-complement protein C5 antibody comprises a light chain having an amino acid sequence as shown in SEQ ID NO.1 and a heavy chain having an amino acid sequence as shown in SEQ ID NO.7.
[0045] Among them, the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2, the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 in the light chain variable region are shown in SEQ ID NO.3, 4, and 5, respectively; the amino acid sequence of the light chain constant region is shown in SEQ ID NO.6.
[0046] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.8, the amino acid sequences of the complementarity determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region are shown in SEQ ID NO.9, 10, and 11, respectively; the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO.12.
[0047] Table 1 Sequence information of amino acid sequences SEQ ID NO.1 to 10: Example 2 Enzyme-linked immunosorbent assay kit for detecting soluble membrane attack complex SC5b-9: In this embodiment, the main components of the ELISA reagent / ELISA kit for detecting the soluble membrane attack complex SC5b-9 include: capture antibody, detection antibody, enzyme-labeled antibody, diluent, washing solution, color development solution, and reaction termination solution.
[0048] Among them, capture antibody: anti-human complement protein C9 antibody (purchased from Foshan Sichuang Biotechnology Co., Ltd., catalog number #SY-ab220505).
[0049] Detection antibody: the anti-complement protein C5 antibody of Example 1 of the present application.
[0050] Enzyme-labeled antibody: HRP-labeled mouse anti-goat IgG antibody.
[0051] Diluent: 0.1 M sodium bicarbonate buffer solution (pH = 9.6).
[0052] Washing solution: PBST buffer (0.05% by volume Tween-20, pH = 7.4).
[0053] Color developing solution: single component 3,3',5,5'-tetramethylbenzidine (TMB) color developing solution.
[0054] Blocking solution: It is prepared by diluting bovine serum albumin (BSA) with PBS buffer (pH=7.4); wherein the concentration of the blocking solution is 1% (mass volume ratio w / v).
[0055] Reaction termination solution: 1M HCl aqueous solution.
[0056] The working principle of this kit is based on the double antibody sandwich method to detect soluble membrane attack complex SC5b-9: first, the anti-human complement protein C9 antibody is coated on the ELISA plate as the capture antibody; then, the human SC5b-9 standard or sample is added to the microwells of the ELISA plate, and the human SC5b-9 protein in the standard or sample binds to the capture antibody solid-phase on the ELISA plate; then, the anti-complement protein C5 antibody is added to the microwells of the ELISA plate, and the anti-complement protein C5 antibody is used as the detection antibody to capture the soluble membrane attack complex SC5b-9; finally, HRP-labeled mouse anti-goat IgG antibody is added to the microwells of the ELISA plate, and the unbound HRP-labeled mouse anti-goat IgG antibody is washed and the color substrate (TMB) is added. TMB is converted into blue under the catalysis of horseradish peroxidase, and converted into the final yellow under the action of acid. The depth of color is positively correlated with the human SC5b-9 protein in the sample. The absorbance (OD value) was measured at a wavelength of 450 nm using an enzyme-labeled instrument, and the concentration of human SC5b-9 protein in the sample was calculated by drawing a standard curve.
[0057] The detection kit is based on the double antibody sandwich method to detect the soluble membrane attack complex SC5b-9, which specifically includes the following steps: Step 201, use a diluent to prepare an anti-complement protein C9 antibody working solution with a concentration of 2.5 ug / mL; add the anti-complement protein C9 antibody working solution to the ELISA plate, 50 μL / well, incubate at 4°C for 12 to 18 hours or 37°C for 2 hours, and discard the solution in the microwells of the ELISA plate; then, add a washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes / time.
[0058] Step 202, add blocking solution to the ELISA plate, 300 μL / well, incubate at 37°C for 1 to 2 hours, and discard the solution in the microwells of the ELISA plate; then, add washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes each time.
[0059] Step 203, add gradient concentration standard solution or sample solution to be tested to the microwells of the ELISA plate, 50 μL / well, incubate at 37°C for 1 hour, and discard the solution in the microwells of the ELISA plate; then, add washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes each time.
[0060] Wherein, the gradient concentration standard solution: the terminal complement complex SC5b-9 is prepared into a gradient concentration standard solution of 0 ng / mL to 500 ng / mL using a diluent.
[0061] Sample solution to be tested: dilute the blood sample 10 times with diluent; specifically: 20 μL of blood sample, 180 μL of diluent.
[0062] Step 204, using a diluent to prepare an anti-complement protein C5 antibody working solution with a concentration of 0.062 μg / mL to 0.25 μg / mL; adding the anti-complement protein C5 antibody working solution to the microwells of the ELISA plate, 50 μL / well, incubating at 37° C. for 1 hour, and discarding the solution in the microwells of the ELISA plate; then, adding a washing solution to the microwells of the ELISA plate, 300 μL / well, washing three times, 2 minutes each time.
[0063] Step 205, dilute the HRP-labeled mouse anti-goat IgG antibody with a diluent to form an HRP-labeled mouse anti-goat IgG antibody working solution, with a dilution ratio of 1:10000 to 1:20000 (mass volume ratio w / v); add the HRP-labeled mouse anti-goat IgG antibody working solution to the microwells of the ELISA plate, 50 μL / well, incubate at 37° C. for 1 hour, and discard the solution in the microwells of the ELISA plate; then, add a washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes / time.
[0064] Step 206, add color developing solution to the microwells of the ELISA plate, 90 μL / well, and react at 37° C. in the dark for 5 to 10 minutes.
[0065] Step 207, add the reaction stop solution to the microwells of the ELISA plate, 50 μL / well, and gently shake the ELISA plate until the color is evenly developed.
[0066] Step 208: Use an ELISA reader to read the OD value of each well in the ELISA plate at a test wavelength of 450 nm, and calculate the concentration of human SC5b-9 protein in the sample by drawing a standard curve.
[0067] From this we get, Figure 2 Standard curve for detection of soluble membrane attack complex SC5b-9 protein is shown.
[0068] from Figure 1 It can be seen that the anti-complement protein C5 antibody and soluble membrane attack complex SC5b-9 of the present application have binding specificity and high affinity, are suitable for plasma sample detection or sample detection from other tissue sources, and have clinical application prospects.
[0069] The kit of this example detects the concentration of human SC5b-9 in blood samples numbered 1# to 32# based on the double antibody sandwich method. The detection results are shown in Table 2.
[0070] Table 2 Detection results of SC5b-9 concentration in blood samples numbered 1# to 32#: Example 3 Enzyme-linked immunosorbent assay reagent / enzyme-linked immunosorbent assay kit for detecting complement protein C5: In this embodiment, the main components of the ELISA reagent / ELISA kit for detecting complement protein C5 include: primary antibody, enzyme-labeled secondary antibody, diluent, washing solution, color developing solution, and reaction stopping solution.
[0071] Wherein, primary antibody: the antibody against complement protein C5 of Example 1 of the present application.
[0072] Enzyme-labeled secondary antibody: HRP-labeled mouse anti-goat IgG antibody.
[0073] Diluent: 0.1 M sodium bicarbonate buffer solution (pH = 9.6).
[0074] Washing solution: PBST buffer (0.05% by volume Tween-20, pH = 7.4).
[0075] Color developing solution: single component 3,3',5,5'-tetramethylbenzidine (TMB) color developing solution.
[0076] Blocking solution: It is prepared by diluting bovine serum albumin (BSA) with PBS buffer (pH=7.4); wherein the concentration of the blocking solution is 1% (mass volume ratio w / v).
[0077] Reaction termination solution: 1M HCl aqueous solution.
[0078] The working principle of this detection kit for detecting complement protein C5 is based on the double antibody sandwich method: first, the anti-complement protein C5 antibody is coated on the ELISA plate; then, the complement protein C5 standard or sample is added to the microwells of the ELISA plate, so that the complement protein C5 in the standard or sample binds to the primary antibody solid phase on the ELISA plate; then, HRP-labeled mouse anti-goat IgG antibody is added, and the unbound HRP-labeled mouse anti-goat IgG antibody is washed and then the color substrate (TMB) is added. TMB is converted into blue under the catalysis of HRP, and converted into the final yellow under the action of acid. The depth of color is positively correlated with the complement protein C5 in the sample. The absorbance (OD value) is measured at a wavelength of 450nm using an ELISA instrument, and the concentration of complement protein C5 in the sample is calculated by drawing a standard curve.
[0079] Among them, the working process of this detection kit for detecting complement protein C5 based on the double antibody sandwich method specifically includes the following steps: Step S301, use a diluent to prepare an anti-complement protein C5 antibody working solution with a concentration of 2.5 ug / mL; add the anti-complement protein C5 antibody working solution to the ELISA plate, 50 μL / well, incubate at 4°C for 12 to 18 hours or 37°C for 2 hours, and discard the solution in the microwells of the ELISA plate; then, add a washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes / time.
[0080] Step S302, add blocking solution to the ELISA plate, 300 μL / well, incubate at 37°C for 1 to 2 hours, and discard the solution in the microwells of the ELISA plate; then, add washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes each time.
[0081] Step S303, add gradient concentration standard solution or sample solution to be tested to the microwells of the ELISA plate, 50 μL / well, incubate at 37°C for 1 hour, and discard the solution in the microwells of the ELISA plate; then, add washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes each time.
[0082] Among them, gradient concentration standard solution: use diluent to prepare the complement protein C5 into gradient concentration standard solution. Sample solution to be tested: use diluent to dilute the blood sample 10 times; specifically: 20μL blood sample, 180μL diluent.
[0083] Step S304, dilute the HRP-labeled mouse anti-goat IgG antibody with a diluent to form an HRP-labeled mouse anti-goat IgG antibody working solution, with a dilution ratio of 1:10000 to 1:20000 (mass volume ratio w / v); add the HRP-labeled mouse anti-goat IgG antibody working solution to the microwells of the ELISA plate, 50 μL / well, incubate at 37°C for 1 hour, and discard the solution in the microwells of the ELISA plate; then, add a washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes / time.
[0084] Step S305, add color developing solution to the microwells of the ELISA plate, 90 μL / well, and react at 37° C. in the dark for 5 to 10 minutes.
[0085] Step S306, adding the reaction stop solution to the microwells of the ELISA plate, 50 μL / well, and gently shaking the ELISA plate until the color is evenly developed.
[0086] Step S307: Use an ELISA reader to read the OD value of each well in the ELISA plate at a test wavelength of 450 nm, and calculate the concentration of complement protein C5 in the sample by drawing a standard curve.
[0087] The enzyme-linked immunosorbent assay kit for detecting complement protein C5 in this embodiment uses a direct enzyme-linked immunosorbent assay (ELISA) method to detect the binding activity of anti-complement protein C5 antibodies and complement protein C5.
[0088] The method for detecting the binding activity of anti-complement protein C5 antibodies and complement protein C5 specifically comprises the following steps: Step S401, using a diluent to prepare an antigen working solution with a concentration of 8 ug / mL with recombinant human complement protein C5; adding the antigen working solution to the microwells of the ELISA plate, 50 μL / well, coating at 4°C for 12 to 18 hours or 37°C for 2 hours, and discarding the solution in the microwells of the ELISA plate; then, adding a washing solution to the microwells of the ELISA plate, 300 μL / well, washing three times, 2 minutes / time.
[0089] Step S402, add blocking solution to the ELISA plate, 300 μL / well, incubate at 37°C for 1 to 2 hours, and discard the solution in the microwells of the ELISA plate; then, add washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes each time.
[0090] Step S403, using a diluent to prepare an anti-complement protein C5 antibody working solution with 7 concentration gradients (the initial concentration is 10 μg / mL, and the 7 concentration gradients are continuously diluted by a factor of 3); adding the anti-complement protein C5 antibody working solution to the microwells of the ELISA plate, 50 μL / well, incubating at 37°C for 1 hour, and discarding the solution in the microwells of the ELISA plate; then, adding a washing solution to the microwells of the ELISA plate, 300 μL / well, washing three times, 2 minutes / time.
[0091] Step S304, dilute the HRP-labeled mouse anti-goat IgG antibody with a diluent to form an HRP-labeled mouse anti-goat IgG antibody working solution, with a dilution ratio of 1:10000 to 1:20000 (mass volume ratio w / v); add the HRP-labeled mouse anti-goat IgG antibody working solution to the microwells of the ELISA plate, 50 μL / well, incubate at 37°C for 1 hour, and discard the solution in the microwells of the ELISA plate; then, add a washing solution to the microwells of the ELISA plate, 300 μL / well, wash three times, 2 minutes / time.
[0092] Step S405, add color developing solution to the microwells of the ELISA plate, 90 μL / well, and react at 37° C. in the dark for 5 to 10 minutes.
[0093] Step S406, adding the reaction stop solution to the microwells of the ELISA plate, 50 μL / well, and gently shaking the ELISA plate until the color is evenly developed.
[0094] Step S407, using an ELISA reader to read the OD value of each well in the ELISA plate at a test wavelength of 450 nm.
[0095] From this we get, Figure 1 The binding activity curve of anti-complement protein C5 antibody and complement protein C5 is shown.
[0096] from Figure 2 It can be seen that the combination of the anti-complement protein C5 antibody of the present application and complement protein C5 is specific, suitable for plasma sample detection or sample detection from other tissue sources, and has clinical application prospects.
[0097] The above is a detailed introduction to an anti-complement protein C5 antibody and its use provided by the present disclosure. This article uses specific examples to illustrate the principles and implementation methods of the present disclosure. The description of the above embodiments is only used to help understand the method of the present disclosure and its core idea. It should be pointed out that for those skilled in the art, without departing from the principles of the present disclosure, several improvements and modifications can be made to the present disclosure, and these improvements and modifications also fall within the scope of protection of the claims of the present disclosure.
Claims
1. An antibody or antigen-binding fragment thereof against complement protein C5, characterized in that: The amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 in the light chain variable region of the antibody or its antigen-binding fragment are shown as SEQ ID NOs. 3, 4, and 5, respectively; the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 in the heavy chain variable region of the antibody or its antigen-binding fragment are shown as SEQ ID NOs. 9, 10, and 11, respectively.
2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The amino acid sequence of the light chain variable region of the antibody or antigen-binding fragment thereof is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region of the antibody or antigen-binding fragment thereof is shown in SEQ ID NO.
8.
3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that: The antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, monoclonal antibody, animal-derived antibody or humanized antibody.
4. A polynucleotide encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3.
5. A biological material containing the polynucleic acid according to claim 4.
6. An antibody conjugate, characterized in that: The antibody conjugate is obtained by coupling the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 with a label, and the label is selected from at least one of enzyme labeling, biotin labeling, fluorescent dye labeling, chemiluminescent dye labeling, and radioactive labeling.
7. Use of any of the following in the preparation of a product for detecting complement protein C5 or soluble membrane attack complex SC5b-9: (I), the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3; and / or (II), the polynucleotide according to claim 4; and / or (III) the biomaterial according to claim 5; and / or (IV) The antibody conjugate according to claim 6.
8. A detection reagent for detecting complement protein C5 or soluble membrane attack complex SC5b-9, characterized in that: The detection reagent comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, and / or the antibody conjugate according to claim 6.
9. A detection kit for detecting complement protein C5 or soluble membrane attack complex SC5b-9, characterized in that: The kit comprises the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, and / or the antibody conjugate according to claim 6.
10. The detection kit according to claim 9, characterized in that The detection kit is selected from an enzyme-linked immunosorbent assay kit, a fluorescent immunoassay kit or a chemiluminescent immunoassay kit.
Citation Information
Patent Citations
Complement binding aptamers and Anti-c5 agents useful in the treatment of ocular disorders
CA3148917A1
Neoantibodies for diagnosing tissue injury
CN103261893A
Method for detecting CM-TMA biomarkers
CN117480393A
Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients
US20180237509A1
